RGLS Share Price

Open 1.60 Change Price %
High 1.65 1 Day -0.05 -3.12
Low 1.50 1 Week 0.15 10.71
Close 1.55 1 Month -0.10 -6.06
Volume 605483 1 Year -4.29 -73.46
52 Week High 6.25
52 Week Low 0.94
RGLS Important Levels
Resistance 2 1.69
Resistance 1 1.63
Pivot 1.57
Support 1 1.47
Support 2 1.41
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
STRT 32.15 30.16%
WRES 0.09 28.57%
TBBK 6.45 27.47%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
EHTH 14.18 20.78%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
ROSE 10.35 -48.20%
ROSE 10.35 -48.20%
DVOX 0.05 -44.44%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 2
As on 28th Apr 2017 RGLS Share Price closed @ 1.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.79 & Buy for SHORT-TERM with Stoploss of 1.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for April
1st Target up-side 2.09
2nd Target up-side 2.39
3rd Target up-side 2.7
1st Target down-side 1.21
2nd Target down-side 0.91
3rd Target down-side 0.6
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
RGLS Latest News
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.